Author

N. Lounsbury

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:clustering· 1 Approach:deep learning· 1 Research Focus:phylogenetics / evolution· 1 Assay:proteomics· 1

Frequent Co-Authors

A. A. Lo· 2 shared A. Wallace· 2 shared C. Havnar· 2 shared D. Oreper· 2 shared X. Pechuan-Jorge· 2 shared C. Rose· 1 shared G.-Y. Yang· 1 shared H. Gurung· 1 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. A. Lo

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Graph-pMHC: Graph Neural Network Approach to MHC Class II Peptide Presentation and Antibody Immunogenicity

W. J. Thrift, J. Perera, S. Cohen, N. Lounsbury, H. Gurung, C. Rose, J. Chen, S. Jhunjhunwala, K. Liu

The paper introduces graph-pMHC, a graph neural network for predicting MHC Class II peptide presentation and improves antibody immunogenicity risk prediction.

bioRxiv · Jan 19, 2023Immunology

Origins and timing of emerging lesions in advanced renal cell carcinoma

A. Wallace, S. Porten, A. A. Lo, D. Oreper, N. Lounsbury, C. Havnar, X. Pechuan-Jorge, O. Zill, M. Meng

This study uses multi-region sequencing to analyze the origins and timing of tumor lesions in advanced renal cell carcinoma, finding that metastases often emerge early and VTT forms later through inflammatory processes.

bioRxiv · Jun 27, 2021Cancer Biology

Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies

A. A. Lo, A. Wallace, D. Oreper, N. Lounsbury, C. Havnar, X. Pechuan-Jorge, T. D. Wu, R. Bourgon, R. Jones, K. Krogh, G.-Y. Yang, O. A. Zill

The paper analyzes tumor evolution across cancer types to identify factors affecting neoantigen targeting in immunotherapy.

bioRxiv · Mar 15, 2021Cancer Biology